Lumonus

Name: Lumonus
Brand: Luminus

Lumonus is a radiation oncology–focused AI-assisted workflow platform that integrates with clinical systems to extract clinical information, reduce manual documentation, and standardize care pathways within existing oncology workflows.

3 Ref Customers

LinkedIn 4K|Website|FTEs 61

Published Sep 3, 2026

01Common complaints

- If a full Oncology Information System (OIS) is required - ARIA or MOSAIQ (or equivalent OIS) are designed to be the oncology EMR backbone; Lumonus appears to be additive rather than a replacement. - If procurement requires clearly published security attestations - If the vendor risk process requires SOC 2 Type II and/or ISO 27001 documentation to be publicly available (or immediately available), Lumonus’ public materials (as accessed here) may be insufficient. - If independently validated clinical outcomes are required before deployment - If an organization needs peer-reviewed evidence or large-scale independent evaluations before deploying AI in clinical workflows, Lumonus’ publicly accessible materials may not meet that requirement. - If the integration environment is highly constrained - Environments with limited interface capacity, strict change freezes, or complex legacy OIS/TPS setups may struggle to onboard an additional workflow layer. - If the primary need is treatment planning automation at the TPS layer - RayStation’s protocol-driven planning automation and RayCare workflow engine may be a more direct fit for plan automation–centric projects. - Current limitations acknowledged by the vendor - Not clearly enumerated in accessible Lumonus pages captured here. - Roadmap items - Public roadmap details and dates are not clearly published in sources accessed. - Scale limitations - Not publicly documented. - Security/compliance gaps (publicly visible) - While the vendor claims HIPAA compliance for at least one component, Lumonus does not publicly document SOC 2 or ISO certifications or detailed security controls on accessible pages captured here. - Technical/integration constraints - Not publicly detailed; given the environment (radiation oncology systems), integration complexity and data quality are likely the key risks.

02Why they buy

- Observed vendor positioning and likely differentiators (subject to buyer validation) - Radiation oncology–specific AI-assisted workflow layer embedded into care processes. - Care pathway and directive implementation framing that focuses on standardization and clinician guidance. - Areas where competitors have advantages - Incumbent OIS vendors - Established compliance programs and long operational histories in regulated clinical software. - Deep integration and entrenched workflows across oncology services. - RaySearch/MIM/Radformation - Established reputations in specific parts of the radiation oncology toolchain (TPS automation, imaging/workflow tooling, QA/automation modules).

03Field reports

- Publicly accessible case studies - Lumonus' website and blog include announcements and narrative descriptions of product modules and partnerships, but the pages accessed in this research did not expose detailed, independently validated outcome case studies with rigorous before/after metrics. - Example: Clinical decision support / pathways post (vendor-authored) - A Lumonus blog post describing a clinical decision support system for implementing care pathways outlines how Lumonus workflows guide oncologists through templated data collection and pre-population of prescription/treatment information. - Critical evaluation - The post describes intended workflow and capabilities but does not provide independently verified clinical outcomes (e.g., error reduction, time saved, adherence improvements). - Buyers should request peer-reviewed evaluations, internal audit results, or at minimum a structured outcomes report with methodology. - Example: Collaboration announcement with a major cancer center (vendor press-style) - Lumonus announced a collaboration with a prominent cancer center to advance radiation therapy treatment planning. - Critical evaluation - Collaboration announcements can indicate access to clinical expertise, but they are not equivalent to validated performance evidence or broad deployability. - Buyers should ask whether the collaboration is research-only, a pilot, or a production deployment; what deliverables exist; and whether any results are publishable.

Important context about review availability

Lumonus is a specialized radiation oncology workflow product and is not broadly present on mainstream SaaS review sites under the exact “Lumonus” listing based on accessible sources; many review platform results for similar names refer to unrelated products.
As a result, this section relies primarily on vendor-published testimonials and healthcare community discussions about adjacent systems rather than large volumes of third-party reviews specific to Lumonus.

Vendor-published testimonials (positive)

- The vendor site includes customer-quote style testimonials. A vendor-published testimonial attributes responsiveness and alignment with patient care priorities to the Lumonus team (example attribution: Tacoma Radiation Oncology Centers — WA, USA). - Limitations of this evidence - These are curated vendor testimonials; they do not provide the distribution of customer sentiment, the selection methodology, or the prevalence of negative experiences.

Independent/community signals (mixed, mostly about the broader ecosystem rather than Lumonus)

- Radiation oncology IT community discussions (e.g., Reddit) - Threads discuss pain points of OIS migrations and integration work (e.g., MOSAIQ-to-ARIA transitions), including extra costs and workflow considerations. - Example negative/cautionary comment (about migration costs, not Lumonus): “There was a significant extra cost to migrate the Mosaiq database to Aria and we opted not to do this.” - Example mixed comment (about Varian environment integration, not Lumonus): “Overall I’m extremely happy with the better integration of the Varian environment…” - Why this matters to Lumonus - If Lumonus positions itself as integrated into existing workflows, it will likely have to coexist with ARIA/MOSAIQ/Epic/RayStation environments. Community comments suggest integration and migration complexity can be a major driver of dissatisfaction, timeline risk, and cost overruns.

Why customers might choose Lumonus (hypotheses supported by vendor positioning and market context)

Preference for workflow-integrated assistance rather than replacing the OIS.
Interest in reducing documentation burden and standardizing directives and care pathways.
Interest in AI-based consultation support as described by the vendor.

Why customers might not purchase or might churn (inferred risk factors; verify with references)

If security artifacts (SOC 2/ISO reports) are not available quickly, procurement may stall.
If integration requires heavy professional services, time-to-value may be long.
If clinicians perceive AI output as not sufficiently trustworthy or auditable, adoption may lag.
If the product duplicates capabilities provided by existing investments (RayCare, Radformation automation, OIS enhancements), the incremental ROI may be limited.

04Best fit

Ideal Customer Profile

- Organization sizes - Best-fit likely mid-to-large radiation oncology providers where workflow complexity and staff burden are sufficient to justify an additional workflow layer. - Practical heuristic ranges (to validate) - Multi-site cancer centers, health systems, or networks with multiple radiation oncology physicians and dosimetry teams. - Industries and verticals where adoption is strongest - Radiation oncology departments within hospitals - Multi-site oncology networks - Academic cancer centers (particularly those running care pathway standardization initiatives) - Roles and personas - Decision makers - Department chair / radiation oncology leadership - CMIO/clinical informatics leadership - IT/security leadership (HIPAA/BAA compliance and risk) - End users - Radiation oncologists - Dosimetrists - Nurses/therapists involved in radiation oncology workflows - Administrative staff managing directives and documentation - Pain points the product addresses (based on vendor narrative) - Administrative burden and manual documentation workload - Workflow inconsistency across providers/sites - Complexity of capturing staging and diagnosis data in a structured manner - Qualification criteria (good fit) - Existing radiation oncology digital ecosystem (ARIA/MOSAIQ/Epic/RayStation) where Lumonus can integrate without requiring replacement of core systems. - Strong executive sponsorship for workflow change management. - Willingness to run a governed pilot with measurable workflow KPIs. - Deal disqualifiers (poor fit) - Centers without IT integration capacity or without bandwidth for workflow redesign. - Procurement programs requiring publicly posted SOC 2/ISO evidence up-front (if Lumonus can only provide such reports under NDA or not at all). - Very small clinics where ROI may not justify integration effort.

05The pitch

What the product does (core value proposition in objective terms)

Lumonus is a radiation oncology–focused AI-assisted workflow platform embedded into clinical workflows, intended to reduce manual documentation and support care teams in standardizing and executing directives and care pathways.
Vendor materials emphasize integration with clinical workflows and automated extraction of clinical information (likely from existing clinical systems and documents) rather than requiring clinicians to re-enter data.

Target market and market positioning

Target users appear to be radiation oncology care teams (physicians, dosimetrists, and broader department workflows).
Positioned as a workflow and clinical decision support layer in radiation oncology, rather than a full Oncology Information System (OIS) such as ARIA or MOSAIQ.

Get a comprehensive analysis of Lumonus including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →